Hartz S - Search Results

1

Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study.

Dignass A, Redondo I, Streit P, Hartz S, Gurses G, Knight H, Barlow S, Harvey N, Hunter T. Dignass A, et al. Among authors: hartz s. Curr Med Res Opin. 2023 Dec;39(12):1695-1705. doi: 10.1080/03007995.2023.2278695. Epub 2023 Dec 15. Curr Med Res Opin. 2023. PMID: 37927078

2

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe.

Gisbert JP, Streit P, Redondo I, Hartz S, Knight H, Quinones E, Harvey N, Palace V, Hunter Gibble T. Gisbert JP, et al. Among authors: hartz s. Curr Med Res Opin. 2023 Sep;39(9):1205-1214. doi: 10.1080/03007995.2023.2244414. Epub 2023 Aug 28. Curr Med Res Opin. 2023. PMID: 37545338

3

Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.

Dovizio M, Hartz S, Buzzoni C, Redondo I, Nedeljkovic Protic M, Birra D, Perrone V, Veronesi C, Degli Esposti L, Armuzzi A. Dovizio M, et al. Among authors: hartz s. Adv Ther. 2024 Jun;41(6):2282-2298. doi: 10.1007/s12325-024-02840-x. Epub 2024 Apr 15. Adv Ther. 2024. PMID: 38619721 Free PMC article.

4

Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn's Disease: A Real-World Global Study.

Atreya R, Redondo I, Streit P, Protic M, Hartz S, Gurses G, Knight H, Barlow S, Harvey N, Hunter Gibble T. Atreya R, et al. Among authors: hartz s. Crohns Colitis 360. 2024 Aug 10;6(3):otae047. doi: 10.1093/crocol/otae047. eCollection 2024 Jul. Crohns Colitis 360. 2024. PMID: 39281848 Free PMC article.

5

Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis.

Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, Kroep S, Halfpenny N, Arcà E, Hoque S. Dignass A, et al. Among authors: hartz s. Adv Ther. 2024 Dec;41(12):4446-4462. doi: 10.1007/s12325-024-03003-8. Epub 2024 Oct 15. Adv Ther. 2024. PMID: 39404996 Free PMC article.

6

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.

Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Johansson EC, et al. Among authors: hartz s. J Med Econ. 2018 Aug;21(8):810-820. doi: 10.1080/13696998.2018.1474747. Epub 2018 Jun 6. J Med Econ. 2018. PMID: 29873270 Free article.

7

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Johansson E, Nuñez M, Svedbom A, Dilla T, Hartz S. Johansson E, et al. Among authors: hartz s. Clinicoecon Outcomes Res. 2018 Nov 12;10:747-759. doi: 10.2147/CEOR.S167727. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30519064 Free PMC article.

8

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.

Schweikert B, Malmberg C, Núñez M, Dilla T, Sapin C, Hartz S. Schweikert B, et al. Among authors: hartz s. BMJ Open. 2020 Aug 13;10(8):e032552. doi: 10.1136/bmjopen-2019-032552. BMJ Open. 2020. PMID: 32792421 Free PMC article.

9

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, Lomaga M, Dutronc Y, Henneges C, Wilhelm S, Hartz S, Paul C; IXORA-S investigators. Reich K, et al. Among authors: hartz s. Br J Dermatol. 2017 Oct;177(4):1014-1023. doi: 10.1111/bjd.15666. Epub 2017 Jul 19. Br J Dermatol. 2017. PMID: 28542874 Clinical Trial.

10

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.

Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C. Al Sawah S, et al. Among authors: hartz s. J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22. J Med Econ. 2017. PMID: 28760056 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters